Skip to main content
Retour
ARWR logo

Arrowhead Pharmaceuticals, Inc.

Qualité des données : 100%
ARWR
NASDAQ Healthcare Biotechnology
60,77 €
▲ 4,50 € (8,00%)
Cap. Boursière : 8,51B
Fourchette du Jour
57,52 € 62,81 €
Fourchette 52 Semaines
9,57 € 76,76 €
Volume
2 732 341
Moyenne 50J / 200J
63,61 € / 41,41 €
Clôture Précédente
56,27 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -5217,5 0,2
P/B 18,3 3,0
ROE % -0,5 3,6
Net Margin % -0,2 3,8
Rev Growth 5Y % 56,5 9,9
D/E 0,8 0,2

Objectif de Cours des Analystes

Hold
78,78 € +29.6%
Low: 35,00 € High: 110,00 €
BPA Prévisionnel
-3,21 €
CA Est.
454,26M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,01 €
1,52 € – 4,65 €
1,62B 5
FY2029 -1,27 €
-1,96 € – -0,64 €
886,47M 2
FY2028 -2,81 €
-4,10 € – -1,10 €
548,60M 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-05 0,04 € 0,22 € +491,9%
2025-11-25 -0,11 € -0,18 € -61,3%
2025-08-07 -0,94 € -1,26 € -34,0%
2025-05-12 -0,06 € 2,75 € +4683,3%
2025-02-10 -0,42 € -1,39 € -231,0%
2024-11-26 -1,05 € -1,38 € -31,4%
2024-08-08 -0,58 € -1,38 € -137,9%
2024-05-09 -0,06 € -1,02 € -1600,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 56,50% annually over 5 years — strong growth
Generating 156,89M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 23201,65%
Capital efficient — spends only 2,73% of revenue on capex
Interest coverage of 1,10× — tight debt servicing

Croissance

Revenue Growth (5Y)
56,50%
Revenue (1Y)23258,15%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-0,50%
ROIC8,86%
Net Margin-0,20%
Op. Margin11,86%

Sécurité

Debt / Equity
0,79
Current Ratio4,86
Interest Coverage1,10

Valorisation

P/E Ratio
-5217,51
Forward P/EN/A
P/B Ratio18,26
EV/EBITDA87,95
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 23258,15% Revenue Growth (3Y) 85,62%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 56,50% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 829,45M Net Income (TTM) -1,63M
ROE -0,50% ROA -0,12%
Gross Margin 97,12% Operating Margin 11,86%
Net Margin -0,20% Free Cash Flow (TTM) 156,89M
ROIC 8,86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,79 Current Ratio 4,86
Interest Coverage 1,10
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5217,51 Forward P/E N/A
P/B Ratio 18,26 P/S Ratio 10,26
PEG Ratio 28,35 Forward PEG N/A
EV/EBITDA 87,95 Fwd EV/EBITDA N/A
Forward P/S 18,73 Fwd Earnings Yield N/A
FCF Yield 1,84%
Market Cap 8,51B Enterprise Value 8,65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 829,45M 3,55M 240,74M 243,23M 138,29M
Net Income -1,63M -599,49M -205,28M -176,06M -140,85M
EPS (Diluted) -0,01 -5,00 -1,92 -1,67 -1,36
Gross Profit 805,52M 3,55M 240,74M 243,23M 138,29M
Operating Income 98,35M -601,08M -205,00M -178,51M -149,04M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,39B 1,14B 765,55M 691,94M 710,15M
Total Liabilities 881,88M 948,74M 478,39M 273,60M 301,33M
Shareholders' Equity 466,05M 185,44M 271,34M 398,52M 408,82M
Total Debt 366,28M 851,91M 383,50M 81,58M 25,55M
Cash & Equivalents 226,55M 102,69M 110,89M 108,01M 184,43M
Current Assets 950,64M 695,47M 419,52M 405,30M 384,60M
Current Liabilities 195,49M 103,17M 105,46M 138,85M 146,54M